Chelation Therapy

Toxic Metals in the Body

It is impossible to provide effective, up-to-date healthcare without giving special consideration to environmental medicine. An integral part of this is chelation therapy.

In several thousand patients, we have detected highly toxic metals such as mercury, lead, arsenic, cadmium, tin, etc. The peculiarity about this is that these metals are not only present in the blood, but are stored throughout all the tissues of the body. Since they are particularly fat-soluble (lipophilic), they tend to be stored in the extremely fat-rich nerve tissue where they form depots.

A person's individual ability to detoxify varies greatly. In chronically ill patients, we generally find limited and impaired detoxification ability. We can very precisely measure this using the enzymes of glutathione S transferase (GST T1, GST M1, GST P1) as well as NAT 2 and SOD2 (Phase II) and individually selected enzymes of Phase I (see Environmental Toxin Diagnostics).

With DMPS, DMSA and EDTA infusions, we can selectively remove highly toxic metals from nerve tissue, connective tissue, and internal organs. The majority of our patients report significant improvements to their overall health.

Exposure to toxic metals – a trigger factor for multisystemic diseases

Toxic metal exposure can play a causative role in the development of chronic inflammatory multisystemic diseases by directly promoting inflammation and at the same time negatively influencing the regulatory cycle between inflammation, mitochondriopathy, oxidative and nitrosative stress. As such, they contribute decisively to the permanent disruption of immune tolerance through chronic inflammation, which in turn makes the body more "sensitive" and intolerant to many other trigger factors. This correlation explains the "scope" of the diseases associated with metal reactions. Please also refer to the CERCLA list.

Exposure to toxic metal can play a role in numerous endemic diseases

Exposure to toxic metal can play a role in numerous endemic diseases

Studies suggest that metal-induced oxidative stress cannot only contribute significantly to the development of arteriosclerosis, but also to the development of type 2 diabetes. In the mouse model for diabetes, a reduction of copper exposure through chelation therapy reduces both the production of free radicals and insulin resistance. Lead pollution leads to oxidative damage of blood vessels and as a result, promotes the progression of chronic obstructive pulmonary diseases and chronic renal insufficiency. Clinically, the inflammation-promoting effect of metals can also be of primary importance. Through the release of cobalt abrasion particles from hip implants, cobalt activates the toll-like receptor-4 (TLR4) signaling pathway and increases the release of TNF-alpha and IL-8. In fact, cobalt blood levels correlate with the likelihood of needing replacement of the artificial joint.

Chelation therapy has always been of particular value in the treatment of arteriosclerosis. Generally, successful results can be precisely verified with ultrasound.

Individual sensitivity/receptivity is important

The nature and extent of the symptoms depend not only on the scope of the toxic metal exposure but also on the patient's individual sensitivity. This relates to a specific genetic sensitivity (e.g., Phase II detoxification by GST enzymes, etc.), but, above all, to functional resistance, i.e., the ability of the organism to compensate for and repair any damage or stress that occurs. For example, a good supply of essential trace elements (observable in the whole blood mineral profile), an adequate supply of vitamins (B and D vitamins, folic acid, coenzyme Q10) and antioxidants promote "resistance."

Member of the Medical Society for Clinical Metal Toxicology,